glycopyrrolate + formoterol + fluticasone

A triple combination inhalation therapy consisting of glycopyrrolate (a long-acting muscarinic antagonist), formoterol fumarate (a long-acting beta2-agonist), and fluticasone (an inhaled corticosteroid). This specific combination is intended for the maintenance treatment of chronic obstructive pulmonary disease (COPD) to provide simultaneous bronchodilation and anti-inflammatory effects. While Pearl Therapeutics (a subsidiary of AstraZeneca) is a leader in developing inhaled combinations using its proprietary Co-Suspension Aerosphere technology, this specific triple combination (utilizing fluticasone) is not a recognized product in their clinical pipeline. Pearl's primary triple-therapy candidate is PT010 (marketed as Breztri Aerosphere), which contains budesonide as the corticosteroid component. The dual combination developed by Pearl, PT003 (marketed as Bevespi Aerosphere), contains only glycopyrrolate and formoterol. The inclusion of fluticasone in this drug name likely represents a misidentification of the corticosteroid component used in Pearl's triple-therapy programs.